171 related articles for article (PubMed ID: 22036088)
21. Neoadjuvant and adjuvant chemotherapy with high-dose ifosfamide, doxorubicin, cisplatin and high-dose methotrexate in non-metastatic osteosarcoma of the extremities: a phase II trial in Japan.
Kudawara I; Aoki Y; Ueda T; Araki N; Naka N; Nakanishi H; Matsumine A; Ieguchi M; Mori S; Myoui A; Kuratsu S; Hashimoto N; Yoshikawa H
J Chemother; 2013 Feb; 25(1):41-8. PubMed ID: 23433444
[TBL] [Abstract][Full Text] [Related]
22. Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial.
Piperno-Neumann S; Le Deley MC; Rédini F; Pacquement H; Marec-Bérard P; Petit P; Brisse H; Lervat C; Gentet JC; Entz-Werlé N; Italiano A; Corradini N; Bompas E; Penel N; Tabone MD; Gomez-Brouchet A; Guinebretière JM; Mascard E; Gouin F; Chevance A; Bonnet N; Blay JY; Brugières L; ; ;
Lancet Oncol; 2016 Aug; 17(8):1070-1080. PubMed ID: 27324280
[TBL] [Abstract][Full Text] [Related]
23. Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity: study of 272 patients preoperatively treated with high-dose methotrexate, doxorubicin, and cisplatin.
Bacci G; Ferrari S; Delepine N; Bertoni F; Picci P; Mercuri M; Bacchini P; Brach del Prever A; Tienghi A; Comandone A; Campanacci M
J Clin Oncol; 1998 Feb; 16(2):658-63. PubMed ID: 9469355
[TBL] [Abstract][Full Text] [Related]
24. IAP Chemotherapy Regimen Is a Viable and Cost-effective Option in Children and Adolescents With Osteosarcoma: A Comparative Analysis With MAP Regimen on Toxicity and Survival.
Verma P; Jain S; Kapoor G; Tripathi R; Sharma P; Doval DC
J Pediatr Hematol Oncol; 2021 May; 43(4):e466-e471. PubMed ID: 32925402
[TBL] [Abstract][Full Text] [Related]
25. EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment.
Whelan JS; Bielack SS; Marina N; Smeland S; Jovic G; Hook JM; Krailo M; Anninga J; Butterfass-Bahloul T; Böhling T; Calaminus G; Capra M; Deffenbaugh C; Dhooge C; Eriksson M; Flanagan AM; Gelderblom H; Goorin A; Gorlick R; Gosheger G; Grimer RJ; Hall KS; Helmke K; Hogendoorn PC; Jundt G; Kager L; Kuehne T; Lau CC; Letson GD; Meyer J; Meyers PA; Morris C; Mottl H; Nadel H; Nagarajan R; Randall RL; Schomberg P; Schwarz R; Teot LA; Sydes MR; Bernstein M;
Ann Oncol; 2015 Feb; 26(2):407-14. PubMed ID: 25421877
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of pirarubicin-cisplatin chemotherapy in the treatment for refractory and recurrent high-grade osteosarcoma: experience of a single institute.
Qi WX; He AN; Tang LN; Shen Z; Yao Y
Med Oncol; 2012 Sep; 29(3):2229-33. PubMed ID: 21748427
[TBL] [Abstract][Full Text] [Related]
27. Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities. Results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin.
Bacci G; Picci P; Ferrari S; Ruggieri P; Casadei R; Tienghi A; Brach del Prever A; Gherlinzoni F; Mercuri M; Monti C
Cancer; 1993 Dec; 72(11):3227-38. PubMed ID: 8242546
[TBL] [Abstract][Full Text] [Related]
28. Risk-Based Therapy for Localized Osteosarcoma.
Venkatramani R; Murray J; Helman L; Meyer W; Hicks MJ; Krance R; Lau C; Jo E; Chintagumpala M
Pediatr Blood Cancer; 2016 Mar; 63(3):412-7. PubMed ID: 26501936
[TBL] [Abstract][Full Text] [Related]
29. Doxorubicin and cisplatin with granulocyte colony-stimulating factor as adjuvant chemotherapy for osteosarcoma: phase II trial of the European Osteosarcoma Intergroup.
Ornadel D; Souhami RL; Whelan J; Nooy M; Ruiz de Elvira C; Pringle J; Lewis I; Steward WP; George R; Bridgewater J
J Clin Oncol; 1994 Sep; 12(9):1842-8. PubMed ID: 7521906
[TBL] [Abstract][Full Text] [Related]
30. Comparison of long-term outcome between doublet and triplet neoadjuvant chemotherapy in non-metastatic osteosarcoma of the extremity.
Hong S; Shin SJ; Jung M; Jeong J; Lee YJ; Shin KH; Roh JK; Rha SY
Oncology; 2011; 80(1-2):107-17. PubMed ID: 21677455
[TBL] [Abstract][Full Text] [Related]
31. Combined pre-operative chemotherapy with intra-arterial cisplatin and continuous intravenous adriamycin for high grade osteosarcoma.
Rha SY; Chung HC; Gong SJ; Shim KY; Ahn JB; Yang WI; Shin KH; Yoo NC; Kim JH; Roh JK; Lee CI; Kim BS
Oncol Rep; 1999; 6(3):631-7. PubMed ID: 10203605
[TBL] [Abstract][Full Text] [Related]
32. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group.
Meyers PA; Schwartz CL; Krailo MD; Healey JH; Bernstein ML; Betcher D; Ferguson WS; Gebhardt MC; Goorin AM; Harris M; Kleinerman E; Link MP; Nadel H; Nieder M; Siegal GP; Weiner MA; Wells RJ; Womer RB; Grier HE;
J Clin Oncol; 2008 Feb; 26(4):633-8. PubMed ID: 18235123
[TBL] [Abstract][Full Text] [Related]
33. Relationship of peak serum methotrexate concentration to prognosis and drug tolerance in non-metastatic extremity osteosarcomas.
Wang B; Yao H; Xie X; Yin J; Zou C; Huang G; Shen J
Cancer Chemother Pharmacol; 2018 Aug; 82(2):221-227. PubMed ID: 29808416
[TBL] [Abstract][Full Text] [Related]
34. Sex- and age-related chemotherapy toxicity in patients with non-metastatic osteosarcoma.
Ferrari S; Palmerini E; Staals E; Abate ME; Longhi A; Cesari M; Balladelli A; Pratelli L; Bacci G
J Chemother; 2009 Apr; 21(2):205-10. PubMed ID: 19423475
[TBL] [Abstract][Full Text] [Related]
35. Dose-intense ifosfamide/doxorubicin/cisplatin based chemotherapy for osteosarcoma in adults.
Patel SJ; Lynch JW; Johnson T; Carroll RR; Schumacher C; Spanier S; Scarborough M
Am J Clin Oncol; 2002 Oct; 25(5):489-95. PubMed ID: 12393991
[TBL] [Abstract][Full Text] [Related]
36. Osteosarcoma journey over two decades in India: Small steps, big changes.
Bajpai J; Chandrasekharan A; Simha V; Mandal T; Shah K; Hingmare S; Rangarajan B; Shetty N; Vora T; Ghosh J; Rekhi B; Banavali S; Gupta S
Pediatr Blood Cancer; 2019 Sep; 66(9):e27877. PubMed ID: 31207015
[TBL] [Abstract][Full Text] [Related]
37. SFOP OS94: a randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients.
Le Deley MC; Guinebretière JM; Gentet JC; Pacquement H; Pichon F; Marec-Bérard P; Entz-Werlé N; Schmitt C; Brugières L; Vanel D; Dupoüy N; Tabone MD; Kalifa C;
Eur J Cancer; 2007 Mar; 43(4):752-61. PubMed ID: 17267204
[TBL] [Abstract][Full Text] [Related]
38. Treatment of unresectable or metastatic osteosarcoma with cisplatin or cisplatin-doxorubicin.
Pratt CB; Champion JE; Senzer N; Green AA; Rao B; Douglass E; Meyer WE; Crom DB
Cancer; 1985 Oct; 56(8):1930-3. PubMed ID: 2992753
[TBL] [Abstract][Full Text] [Related]
39. Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide.
Bacci G; Briccoli A; Rocca M; Ferrari S; Donati D; Longhi A; Bertoni F; Bacchini P; Giacomini S; Forni C; Manfrini M; Galletti S
Ann Oncol; 2003 Jul; 14(7):1126-34. PubMed ID: 12853357
[TBL] [Abstract][Full Text] [Related]
40. A phase II study of cisplatin, ifosfamide and epirubicin combination chemotherapy in adults with nonmetastatic and extremity osteosarcomas.
Basaran M; Bavbek ES; Saglam S; Eralp L; Sakar B; Atalar AC; Bilgic B; Ozger H; Onat H
Oncology; 2007; 72(3-4):255-60. PubMed ID: 18185020
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
